Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Michael Wang(The University of Texas MD Anderson Cancer Center), Nirav N. Shah(Medical College of Wisconsin), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Kami J. Maddocks(The Ohio State University), Donald E. Tsai(University of Pennsylvania), Koji Izutsu(Tokyo National Hospital), Binoj C. Nair(The University of Texas Health Science Center at San Antonio), Constantine S. Tam(The Royal Melbourne Hospital), Krish Patel, James N. Gerson(UPMC Hillman Cancer Center), Talha Munir(St James's University Hospital), Youngil Koh(Genome Research Foundation), Toby A. Eyre(Churchill Hospital), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Paolo Abada(University of California, San Diego), Junjie Zhao(Loxo Oncology at Lilly (United States)), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Chan Y. Cheah(The University of Western Australia), Timothy S. Fenske(Medical College of Wisconsin), Benoît Tessoulin(Centre Hospitalier Universitaire de Nantes), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), John F. Seymour(The Royal Melbourne Hospital), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Minna Balbas(Roswell Park Comprehensive Cancer Center), Alvaro J. Alencar(University of Miami), Anita Kumar(Memorial Sloan Kettering Cancer Center), Pier Luigi Zinzani(University of Bologna), Hirokazu Nagai(Nagoya Medical Center), Wojciech Jurczak(The Maria Sklodowska-Curie National Research Institute of Oncology), David Lewis(University Hospitals Plymouth NHS Trust), Yucai Wang(Mayo Clinic), Ian W. Flinn(Sarah Cannon), Chunxiao Wang(Eli Lilly (United States)), Richard A. Walgren(Loxo Oncology at Lilly (United States))
Cited by 106
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k